GlassScriptPhysician profile
Charles L Valone
NPI 1538165337
$48,036.94
in general payments reported to CMS, 2019-2025
72 companies · $5,617 in 2025
The $5,617 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $4,115 · 2021: $5,944 · 2022: $5,267 · 2023: $6,157 · 2024: $5,334 · 2025: $5,617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17K · Education: $277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16,831.17 |
| Education | $277.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $8,042.66 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $4,495.45 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $3,734.65 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $3,662.04 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Amgen INC. | $2,722.14 | 2019-2025 | Repatha, Otezla, Evenity |
| Teva Pharmaceuticals USA, INC. | $2,255.92 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Janssen Pharmaceuticals, INC | $2,237.52 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $1,658.37 | 2021-2025 | |
| Axsome Therapeutics, INC. | $1,406.25 | 2022-2025 | Auvelity, Sunosi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,308.51 | 2020-2025 | Caplyta |
| Lilly USA, LLC | $1,138.75 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $833.90 | 2019-2025 | Rexulti, Nuedexta |
| Alkermes, INC. | $803.18 | 2021-2025 | Lybalvi, Aristada |
| Mylan Specialty L.P. | $745.96 | 2019-2024 | Yupelri, Yupelri |
| Corcept Therapeutics | $738.89 | 2019-2025 | Korlym |
Show all 72 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Valone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.